Skip to main content

Horizon Discovery to Screen Actelion Drug Compounds

NEW YORK (GenomeWeb News) — Translational genomics company Horizon Discovery will use its X-MAN technology to screen a number of drug compounds and potential patient groups for Actelion Pharmaceuticals.
The agreement covers screening of “a number of Actelion’s lead compounds on a wide panel of genotypes,” Horizon said. The aim is to enable the drug company to predict the selectivity of their compounds against patient genotypes, the drug mechanisms conferred by secondary mutations, and the patient groups that are most likely to respond in clinical trials.
Actelion will pay Horizon an undisclosed sum. The companies will begin work on the project in January 2009, said Horizon.
Horizon Discovery hopes that the project will help it “further prove the potential of our human X-Man models in a screening environment,” Horizon’s Commercial Director, Darrin Disley, said in a statement.
Financial terms of the agreement were not released.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.